KD Logo

Rocket Pharmaceuticals Inc [RCKT] Investment Appeal on the Rise

In a filing, Rocket Pharmaceuticals Inc revealed its insider Militello John unloaded Company’s shares for reported $19051.0 on Apr 22 ’24. In the deal valued at $22.87 per share,833 shares were sold. As a result of this transaction, Militello John now holds 54,406 shares worth roughly $1.19 million.

Then, SOUTHWELL DAVID P sold 10,000 shares, generating $240,520 in total proceeds. Upon selling the shares at $24.05, the Director now owns 114,784 shares.

Before that, SOUTHWELL DAVID P sold 70,000 shares. Rocket Pharmaceuticals Inc shares valued at $1,705,265 were divested by the Director at a price of $24.36 per share. As a result of the transaction, SOUTHWELL DAVID P now holds 95,160 shares, worth roughly $2.08 million.

Goldman initiated its Rocket Pharmaceuticals Inc [RCKT] rating to a Neutral in a research note published on April 02, 2024; the price target was $39. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late October with a ‘”an Overweight”‘ rating. Morgan Stanley began covering RCKT with “an Overweight” recommendation on February 01, 2023. Canaccord Genuity started covering the stock on November 08, 2022. It rated RCKT as “a Buy”.

Price Performance Review of RCKT

On Monday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -0.59% to $21.85. Over the last five days, the stock has lost -8.46%. Rocket Pharmaceuticals Inc shares have fallen nearly -27.09% since the year began. Nevertheless, the stocks have risen 25.36% over the past one year. While a 52-week high of $32.53 was reached on 02/27/24, a 52-week low of $14.89 was recorded on 04/29/24. SMA at 50 days reached $26.44, while 200 days put it at $23.09. A total of 0.73 million shares were traded, compared to the trading of 0.92 million shares in the previous session.

Levels Of Support And Resistance For RCKT Stock

The 24-hour chart illustrates a support level at 21.52, which if violated will result in even more drops to 21.19. On the upside, there is a resistance level at 22.26. A further resistance level may holdings at 22.67. The Relative Strength Index (RSI) on the 14-day chart is 30.88, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.54, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.67%. Stochastics %K at 5.87% indicates the stock is a buying.

The most recent change occurred on November 01, 2022 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.

Most Popular

[the_ad id="945"]